Consensus MaaT Pharma

Equities

Real-time Euronext Paris Other stock markets 08:11:03 29/04/2024 BST			5-day change	1st Jan Change
9.6 ^EUR	+5.96%		+8.84%	+37.54%

04-15	MaaT Pharma: positive data in graft-versus-host disease	CF
04-15	MaaT Pharma Presents Positive 18-Month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event	CI

66efe033aa2b.qyRy5gxB4xEeAovhdU3TLCDH2LZEFQBJreFnCIRnEJ0.yHQ-qWENiihabMCgPCOYY2SIssIXYXAm5Y49QeEKXcqadhqsWDSbSV940g~e3b2a6fe7d8e2e17b7809ac0ca1b5a54

Fragmented feeling?	11-06
But where have the bears gone?	11-03
MaaT Pharma's Immune Disorder Therapy Shows Improved Survival Rate In Clinical Trials	13/12/21	MT